AG
SRPT icon

Aperio Group’s Sarepta Therapeutics SRPT Stock Holding History

Aperio Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$3.39M Buy
19,903
+1,940
+11% +$287K 0.01% 1001
2020
Q3 		$2.52M Buy
17,963
+1,151
+7% +$175K 0.01% 1013
2020
Q2 		$2.69M Buy
16,812
+2,081
+14% +$283K 0.01% 972
2020
Q1 		$1.44M Buy
14,731
+4,720
+47% +$540K 0.01% 1160
2019
Q4 		$1.29M Sell
10,011
-1,027
-9% -$104K ﹤0.01% 1302
2019
Q3 		$832K Sell
11,038
-1,003
-8% -$118K ﹤0.01% 1490
2019
Q2 		$1.83M Buy
12,041
+3,414
+40% +$415K 0.01% 1103
2019
Q1 		$1.03M Sell
8,627
-3,833
-31% -$493K ﹤0.01% 1356
2018
Q4 		$1.36M Buy
12,460
+4,866
+64% +$609K 0.01% 1148
2018
Q3 		$1.23M Buy
7,594
+2,672
+54% +$365K 0.01% 1291
2018
Q2 		$651K Buy
4,922
+1,561
+46% +$147K ﹤0.01% 1629
2018
Q1 		$249K Sell
3,361
-575
-15% -$38.3K ﹤0.01% 2040
2017
Q4 		$219K Buy
+3,936
New +$209K ﹤0.01% 2112

Other funds holding SRPT

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aperio Group's SRPT Position: Q4 2020 in Review

Aperio Group increased its Sarepta Therapeutics (SRPT) stake by 11% in Q4 2020, buying an estimated $287K and bringing the position to 19,903 shares worth $3.39M. The position accounts for 0.01% of the portfolio, ranked #1001.

Aperio Group first reported a position in SRPT in Q4 2017 and has held it in 13 quarters since. 455 funds tracked by Wall St. Rank hold SRPT as of Q4 2020.

  • Aperio Group held 19,903 shares of Sarepta Therapeutics worth $3.39M as of Q4 2020.
  • Aperio Group bought 1,940 Sarepta Therapeutics shares in Q4 2020, an estimated $287K.
  • Sarepta Therapeutics made up 0.01% of Aperio Group's portfolio in Q4 2020, its #1001 holding.
  • Aperio Group first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 13 quarters since.
  • 455 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.